Discover how molecular biomarkers such as HER2, KRAS, and PD-L1 are helping guide treatment selection, clinical trials, and personalized cancer care.
Learn how polygenic risk scores are reshaping cancer prevention by combining thousands of genetic variants to improve risk prediction, personalize screening, and guide earlier preventive care.
Discover how precision medicine is transforming immunotherapy through biomarkers like PD-L1, TMB, and MSI-helping clinicians identify the right patients for the right cancer treatments.
Discover how targeted therapies are transforming precision oncology by matching cancer treatments to genetic mutations, enabling more personalized and effective care.
Learn how targeted therapies match drugs to cancer-driving mutations, advancing precision oncology and improving treatment outcomes.
Learn how genomic profiling identified an EGFR mutation and guided targeted therapy selection in a real-world precision oncology case.
A multidisciplinary community committed to advancing research, education, and clinical standards in precision medicine.
Copyright 2026. American Board of Precision Medicine. All Rights Reserved.
